Qiagen stock

QIA · Xetra · EUR

Compare Qiagen
€45.07Change from previous close: −0.40%Absolute change: −€0.18

Close · November 20, 2026

Price history

+8.56% over the period

1 year: from €41.52 (November 20, 2025) to €45.07 (November 20, 2026), +8.56%.

Show chart data

Closing prices adjusted for splits: the last close of each month.

DateClose
November 20, 2026€45.07
October 30, 2026€45.09
September 30, 2026€38.72
August 31, 2026€37.24
July 31, 2026€35.72
June 30, 2026€33.90
May 29, 2026€31.65
April 30, 2026€29.03
March 31, 2026€34.74
February 27, 2026€41.96
January 30, 2026€44.62
December 30, 2025€40.90
November 28, 2025€43.29
November 20, 2025€41.52

At a glance

  • The company

    Provide sample-to-insight solutions that transform biological samples into molecular insights through consumables and instruments for diagnostics and life sciences

  • Latest results

    Quarter to September 30, 2026 · EPS $0.51 (estimate $0.54)

TickerLandia's take on Qiagen

Analysis calculated by TickerLandia from financial statements and prices, with public rules. Not investment advice. How we analyse stocks

Where the price stands

52-wk low€27.56
52-wk high€47.60

−5.31% from the 52-week high

Analysts · 5 analysts

Average target€43.10−4.37% vs. price

Buy 1 · Hold 4 · Sell 0

TickerLandia Fingerprint: Qiagen

Compared with similar companies: very strong momentum and very low growth.

Financials and price compared with 27 companies in the diagnostics & research industry, worldwide. Momentum and risk compared with 1,160 European stocks.

Position in the group from 0 to 100 (100 = highest value): it describes, it does not rate. Tap a row for the metrics. Calculated on November 22, 2026. An indicator calculated by TickerLandia from financial statements and market data. How it is calculated

Valuation

Qiagen is in line with similar companies

Qiagen's P/E (trailing 12 months): 28.5, in line with the median of a group of 11 similar companies (29.6).

Compared with 11 similar companies

Qiagen's metrics compared with similar companies
MetricQiagenPosition in the groupBand
P/E (trailing 12 months)28.5Middle
Forward P/E19.5Middle
Operating margin26.7%High
ROE10.8%Middle
Debt/equity0.47Middle

Grey band: the middle half of the group; tick: the median; dot: Qiagen. All multiples and dividends

TickerLandia analysisHow it is calculated

The financials

The business in numbers

Revenue

$547.87M

Latest quarter · Q3 2026

Net income

$105.66M

Latest quarter · Q3 2026

Quarterly net margin

19.3%

Latest quarter · Q3 2026

Numbers and valuation

Full valuation
Market cap
€9.31B
P/E
28.5
EPS
€1.58
Volume
958.3K
Daily trading
€46.6M
Dividend yield
0.68%
Last ex-dividend on July 7, 2026

How Qiagen is changing

All results
  • Revenue grew 2.2% a year on average over the last 5 years

  • Profits turn into cash: free cash flow equal to 147% of net income

Returns

Qiagen returns with dividends

€1,000 invested in Qiagen 5 years ago, on November 22, 2021, would be worth €925 today with dividends reinvested: −7.51% in total, −1.55% per year. On price alone it would be €822 (−17.78%).

PeriodQiagenDAX€1,000 becomes
1 month+5.23%−1.98%€1,052
6 months+50.69%+0.26%€1,507
Year to date+10.20%+1.28%€1,102
1 year+14.73%+6.55%€1,147
3 years+25.40%+55.98%€1,254
5 years−7.51%+53.90%€925
10 years+73.40%+132.12%€1,734

Over the last 6 months it has done better than 87% of the stocks in the Healthcare sector.

From 1 year up with dividends reinvested, before taxes; under a year price only. DAX: with dividends. Calculate your investment

The chart in detail

Qiagen: technical analysis

Qiagen is in an uptrend: the price is above its 50- and 200-session moving averages, and the 200-session average is rising. The price is 66.6% below its all-time closing high (€134.88, July 18, 2000).

Trend
Upward
RSI (14 sessions)
69
Between 30 and 70
vs 200-session average
+22.44%

Active signals

  • The price is moving in an unusually narrow range compared with the last year.

    since November 16, 2026

Support and resistance

Price areas where Qiagen has stopped several times in the last year. They describe the chart; they are not forecasts.

  1. Resistance€45.47+0.88%2 touches, last on November 12, 2026
  2. Last price€45.07
  3. Support€44.10−2.16%2 touches, last on February 13, 2026
  4. Support€42.07−6.65%3 touches, last on October 6, 2026
  5. Support€40.14−10.95%2 touches, last on February 23, 2026

Volatility and risk

Over the last year it has moved little with the DAX.

Beta (1 year) vs DAX
0.32
Volatility (60 sessions, annualised)
22.9%
Largest fall in the last year
−39.45%

Close of November 20, 2026. Descriptive data calculated on daily prices: it describes the chart and is not investment advice. Beta and volatility describe the last year and can change a lot from one year to the next. How we calculate it

Qiagen: seasonality

Average monthly price change over 29 years

+3.4%Jan+3.7%Feb−2.8%Mar+0.7%Apr+1.0%May−0.6%Jun+1.8%Jul−0.9%Aug−2.5%Sep+2.8%Oct+4.7%Nov−1.2%Dec

Over the last 29 years, the strongest month for Qiagen has been November: +4.72% on average, positive in 20 years out of 28. The weakest has been March: −2.75% on average, positive in 8 years out of 28.

Show chart data
MonthAverageMedianPositive years
January+3.39%+2.43%16 of 28
February+3.67%+1.16%16 of 28
March−2.75%−1.02%8 of 28
April+0.67%+1.29%15 of 28
May+1.02%+0.12%14 of 28
June−0.58%+0.62%15 of 28
July+1.82%+3.57%17 of 28
August−0.86%−1.08%12 of 29
September−2.47%−2.25%11 of 29
October+2.81%+0.16%15 of 29
November+4.72%+3.01%20 of 28
December−1.17%−0.28%12 of 28

Price change only, dividends excluded. Past seasonality does not predict future moves.

The company

Qiagen and its competitors

Laboratories in molecular diagnostics and life sciences research worldwide use the products of Qiagen N.V., which turns biological samples into molecular insights. Its range covers sample technology consumables such as nucleic acid purification kits and instruments, assays for infectious disease, oncology and sexual and reproductive health testing, research PCR and digital PCR solutions, NGS gene panels and library prep kits, DNA methylation analysis, human ID and forensics assays, and bioinformatics software delivered as a service.

Headquarters
Venlo, Netherlands
Employees
5,400
Qiagen and its competitors
CompanyMarket capOperating marginP/E (trailing 12 months)6 months
QiagenQIA$10.23B26.7%28.5+50.69%
bioMérieuxBIM$11.82B16.0%23.4+25.67%
Eurofins ScientificERF$16.03B14.1%29.6+37.31%
DiaSorinDIA$4.21B22.3%28.6+14.88%
Lonza GroupLONN$54.2B23.5%43.2+32.22%
DiagnostykaDIA$1.27B14.9%20.2−6.62%

Same industry or related industries, similar size. Compare Qiagen with its competitors · Full profile